Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 16:05
04/03/20
04/03
16:05
04/03/20
16:05
IMUX

Immunic

$6.69 /

+1.36 (+25.52%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Fred Lublin, discuss how Immunics' IMU-838 can bridge treatment gaps in Multiple Sclerosis (MS) on an Analyst/Industry conference call to be held on April 10 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 10:25
04/03/20
04/03
10:25
04/03/20
10:25
GILD

Gilead

$78.61 /

+1.65 (+2.14%)

, MYL

Mylan

$14.25 /

+0.34 (+2.44%)

, TEVA

Teva

$8.55 /

+0.43 (+5.30%)

, AMRX

Amneal Pharmaceuticals

$3.02 /

-0.025 (-0.82%)

, ABBV

AbbVie

$74.23 /

-0.895 (-1.19%)

, REGN

Regeneron

$498.01 /

-0.74 (-0.15%)

, ALNY

Alnylam

$102.80 /

-1.58 (-1.51%)

, MRNA

Moderna

$33.88 /

+0.68 (+2.05%)

, INO

Inovio

$7.31 /

-0.19 (-2.53%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor pharma/biotech analysts to hold analyst/industry conference call » 10:21
04/03/20
04/03
10:21
04/03/20
10:21
PFE

Pfizer

$33.66 /

+0.81 (+2.47%)

, LLY

Eli Lilly

$142.95 /

+0.8 (+0.56%)

, MRK

Merck

$77.00 /

+0.09 (+0.12%)

, MRTX

Mirati Therapeutics

$76.21 /

+0.84 (+1.11%)

, AMGN

Amgen

$207.69 /

-1.35 (-0.65%)

, JNJ

Johnson & Johnson

$133.95 /

+0.87 (+0.65%)

, PHGE

BiomX

$7.00 /

+ (+0.00%)

Cantor Fitzgerald…

Cantor Fitzgerald Pharmaceuticals Analyst Chen & Kim, Biotech Analysts Young, Kumar & Kluska, along with Dr. Robert Fine from New York-Presbyterian/Columbia University Medical Center review current treatment paradigm for advanced and metastatic colorectal cancer (CRC) and discuss new treatments for CRC on an Analyst/Industry conference call to be held on April 6 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Guggenheim to hold a virtual conference » 09:07
04/03/20
04/03
09:07
04/03/20
09:07
RCKT

Rocket Pharmaceuticals

$14.18 /

+0.85 (+6.38%)

, ZEAL

Zealand Pharma

$30.95 /

-0.65 (-2.06%)

Healthcare Talks: Genomic…

Healthcare Talks: Genomic Medicines & Rare Diseases 2020 to be held on April 3.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Largest borrow rate increases among liquid names » 08:45
04/03/20
04/03
08:45
04/03/20
08:45
VVUS

VIVUS

$1.35 /

-0.11 (-7.53%)

, LABD

Daily S&P Biotech Bear 3x Shares

$14.49 /

-1.86 (-11.38%)

, USO

United States Oil Fund

$5.11 /

+0.74 (+16.93%)

, JNK

SPDR Barclays High Yield Bond

$92.32 /

+0.6 (+0.65%)

, X

U.S. Steel

$6.12 /

-0.28 (-4.38%)

, TRIL

Trillium Therapeutics

$3.75 /

+0.215 (+6.09%)

, SRNE

Sorrento Therapeutics

$2.02 /

+0.29 (+16.76%)

, DG

Dollar General

$159.94 /

+6.83 (+4.46%)

, MPW

Medical Properties Trust

$15.02 /

-0.16 (-1.05%)

, BMRN

BioMarin

$86.07 /

+2.53 (+3.03%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Vivus (VVUS) 108.36% +44.81, Direxion S&P Biotech Bear 3X (LABD) 6.58% +0.67, United States Oil Fund (USO) 1.46% +0.24, SPDR Barclays Capital High Yield Bond (JNK) 2.32% +0.23, US Steel (X) 4.73% +0.16, Trillium Therapeutics (TRIL) 2.85% +0.14, Sorrento Therapeutics (SRNE) 8.16% +0.12, Dollar General (DG) 0.39% +0.12, Medical Properties Trust (MPW) 0.36% +0.11, and BioMarin (BMRN) 0.35% +0.10.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Teleflex price target lowered to $360 from $450 at Raymond James » 08:40
04/03/20
04/03
08:40
04/03/20
08:40
TFX

Teleflex

$294.78 /

+14.79 (+5.28%)

Raymond James analyst…

Raymond James analyst Lawrence Keusch lowered the firm's price target on Teleflex to $360 from $450 and keeps a Strong Buy rating on the share to account for anticipated reductions in elective surgery volumes, which have been informed by several recent surgeon conversations. Roughly 30% of Teleflex revenues are exposed to elective procedures with UroLift and surgical most impacted, Keusch tells investors in a research note. He assumes more practices will temporarily cease implants as COVID-19 sweeps across the country.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
resTORbio announces delay to ongoing Phase 1b/2a trial of RTB101 » 08:06
04/03/20
04/03
08:06
04/03/20
08:06
TORC

resTORbio

$1.06 /

+0.04 (+3.92%)

resTORbio announced that…

resTORbio announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 alone or in combination with sirolimus, in Parkinson's disease. The trial is being conducted at clinical sites in New Zealand and the enrollment delay is a consequence of the COVID-19 level 4 alert in New Zealand, where all non-essential services have been closed and people have been instructed to stay home. The multicenter, 2:1 randomized, double-blind, placebo-controlled Phase 1b/2a trial is evaluating the safety and tolerability of RTB101 alone or in combination with escalating doses of sirolimus once weekly for 4 weeks in patients with Parkinson's disease. To date, patients have been enrolled in four cohorts and dosed once weekly with 300 mg of RTB101 alone, 2 mg of sirolimus alone, a combination of 300 mg RTB101 and 2 mg of sirolimus, or a combination of 300 mg RTB101 and 4 mg of sirolimus. Results of the interim study analysis after the first 3 cohorts indicated that all 3 dosing regimens were well tolerated and RTB101 300 mg once weekly was observed to cross the blood brain barrier. The concentrations of RTB101 in cerebrospinal fluid in subjects dosed with RTB101 300 mg once weekly monotherapy were higher than expected and based on preclinical models, have the potential to induce autophagy in the brain. Sirolimus at the dose of 2 mg, alone or in combination with RTB101, was not detected in the CSF. Data from the first three cohorts in the study suggest that the concentrations of RTB101 observed in the CSF four hours after dosing were highest when RTB101 was given as a monotherapy. Enrollment and dosing of the RTB101 300 mg in combination with sirolimus 4 mg once weekly cohort has been completed.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 04:55
04/03/20
04/03
04:55
04/03/20
04:55
GILD

Gilead

$76.96 /

+4.41 (+6.08%)

, MYL

Mylan

$13.91 /

-0.34 (-2.39%)

, TEVA

Teva

$8.12 /

-0.35 (-4.13%)

, AMRX

Amneal Pharmaceuticals

$3.05 /

+0.015 (+0.50%)

, ABBV

AbbVie

$75.13 /

+1.655 (+2.25%)

, REGN

Regeneron

$498.75 /

+2.08 (+0.42%)

, ALNY

Alnylam

$104.38 /

-0.13 (-0.12%)

, MRNA

Moderna

$33.20 /

+3.52 (+11.86%)

, INO

Inovio

$7.50 /

-0.19 (-2.47%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Recommendations
Piper reiterates Overweight rating on Boston Scientific, sees bounce back coming » 10:48
04/02/20
04/02
10:48
04/02/20
10:48
BSX

Boston Scientific

$30.51 /

+0.35 (+1.16%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien noted that Boston Scientific updated investors on Q1 business trends and long-term mitigation plans due to the global spread of COVID-19, pointing out that procedural volumes declined extensively in March. First quarter sales growth is expected to be in the range of flat to up slightly, while the company expects the second quarter to be impacted more significantly, noted O'Brien, who expects the company to bounce back once the COVID-19 pandemic recedes and volumes normalize. The analyst reiterates his Overweight rating on the shares following the company's update.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 09:47
04/02/20
04/02
09:47
04/02/20
09:47
GILD

Gilead

$72.64 /

+0.09 (+0.12%)

, MYL

Mylan

$14.00 /

-0.25 (-1.75%)

, TEVA

Teva

$8.34 /

-0.135 (-1.59%)

, AMRX

Amneal Pharmaceuticals

$3.07 /

+0.04 (+1.32%)

, ABBV

AbbVie

$73.07 /

-0.4 (-0.54%)

, REGN

Regeneron

$493.41 /

-3.26 (-0.66%)

, ALNY

Alnylam

$105.05 /

+0.54 (+0.52%)

, MRNA

Moderna

$30.60 /

+0.92 (+3.10%)

, INO

Inovio

$7.44 /

-0.25 (-3.25%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.